IL-17A cytokine pathway approach to the management of ankylosing spondylitis - Certificate of Completion
The spondyloarthritis family of diseases share several clinical, genetic and immunologic features. Ankylosing spondylitis (AS), is distinguished among these conditions by a universal involvement of sacroiliac joint inflammation or fusion. Conventional radiographic evidence of this sacroiliitis has historically been a central classification criterion of AS. It is only recently that it has been acknowledged that radiographic sacroiliitis is a late finding in the disease course of many patients. Patients early in the disease course are therefore potentially excluded by these classification criteria.
In the last decade, the Assessment of SpondyloArthritis international Society (ASAS) therefore proposed new classification criteria. This new classification scheme differentiates between radiographic axial spondyloarthritis (for those with sacroiliitis on a standard radiograph, synonymous with AS), and non-radiographic axial spondyloarthritis (for those with clinical features but no radiographic sacroiliitis. These changes will likely further the goal of initiating treatment earlier in the course of the disease.
This interactive online learning activity is valued at 1.5 Hour(s) of continuing education.
Associate Professor Paul Bird
BMed (Hons), FRACP, PhD, Grad Dip MRI
St George & Sutherland Clinical School
University of New South Wales
VMO, St George Private Hospital, Kogarah, NSW
On completion of this program, participants will be better able to:
- Explain the rationale behind timely and effective treatment escalation in type 2 diabetes
- Identify and assess GP and patient factors contributing to treatment inertia
- Individualise glycaemic targets according to clinical factors and patient circumstances
- Navigate second-line treatment options for type 2 diabetes to select appropriate therapies according to each individual’s clinical needs and circumstances